Sorafenib CAS 284461-73-0 Maʻemaʻe ≥99.0% (HPLC) API Hale Hana Kiʻekiʻe
Hāʻawi Kūʻai ʻo Sorafenib Tosylate a me nā mea waena e pili ana:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
| inoa | Sorafenib |
| Nā huaʻōlelo like | ʻO ke kahua kūʻokoʻa ʻo Sorafenib |
| Helu CAS | 284461-73-0 |
| Helu CAT | RF-API04 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C21H16ClF3N4O3 |
| Kaumaha Molecular | 464.82 |
| ʻO ka mānoanoa | 1.454±0.06 g/cm3 |
| Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia ma DMSO |
| Nā Kūlana Hoʻouna | ʻO ka Mahana Kūlohelohe |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Keʻokeʻo a hiki i ka pauda keʻokeʻo |
| Maʻemaʻe / Kaʻina Hanana | ≥99.0% (HPLC) |
| ʻIkepili | H-NMR, MS |
| Nalo ma ka maloo | ≤1.0% |
| Koena ma ka Ignition | ≤0.10% |
| Hoʻokahi haumia | ≤0.20% (HPLC) |
| Huina paumaele | ≤1.0% (HPLC) |
| Nā Metala Kaumaha | ≤20ppm |
| Akaka o ka Haʻina | Kūlike me ke Kūlana |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | RCC & HCC |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
ʻO Sorafenib Tosylate (CAS: 475207-59-1) kahi ʻano hou o ka lāʻau antitumor multi-target, i hoʻomohala ʻia e ka German Bayer Pharmaceuticals, a hōʻike i ka hana antitumor expansive i nā hoʻokolohua holoholona preclinical.Loaʻa ka Sorafenib i nā papa 200-mg no ka hoʻokele waha a hoʻohana ʻia i ka mālama ʻana o RCC a me HCC.Hiki i ka Sorafenib Tosylate (CAS: 475207-59-1) i ka manawa like ke hoʻopili i nā pūnaewele tumo a me nā kīʻaha koko koko.Loaʻa iā ia ka hopena antitumor pālua: hiki iā ia ke ālai i nā ala transduction hōʻailona cell i hoʻopili ʻia e RAF/MEK/ERK e hoʻopaʻa pololei i ka ulu ʻana o ka cell tumor, ʻoiai ke kāohi pū nei i ka VEGF a me nā platelet derived growth factor (PDGF) i mea e pale ai i ke kūkulu ʻana i ke koko koko hou. nā moku, no laila ke keʻakeʻa nei i ka ulu ʻana o nā cell tumor.ʻO Sorafenib kahi mea paʻa o Raf-1 a me B-RAF a me kekahi mau tyrosine kinases.
